Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
28.81
+1.23 (4.46%)
Nov 21, 2024, 12:18 PM EST - Market open
Simulations Plus Revenue
In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth. Simulations Plus had revenue of $18.66M in the quarter ending August 31, 2024, with 19.42% growth.
Revenue (ttm)
$70.01M
Revenue Growth
+17.52%
P/S Ratio
7.87
Revenue / Employee
$355,396
Employees
197
Market Cap
578.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
| Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
| Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
| Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
| Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Auna S.A. | 1.17B |
| Organogenesis Holdings | 455.04M |
| Surmodics | 126.08M |
| CureVac | 70.57M |
| Mereo BioPharma Group | 1.00M |
SLP News
- 2 days ago - Simulations Plus to Participate in the BTIG Digital Health Forum - Business Wire
- 8 days ago - Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables - Business Wire
- 15 days ago - Simulations Plus to Participate in the Stephens Annual Investment Conference - Business Wire
- 22 days ago - Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations - Business Wire
- 4 weeks ago - Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results - Business Wire
- 6 weeks ago - Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date - Business Wire
- 6 weeks ago - Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings - Business Wire